A First‐in‐Human Phase I Study of GC1118, a Novel Anti‐Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors

LESSONS LEARNED. GC1118 is a novel fully human anti‐epidermal growth factor receptor (EGFR) antibody with unique binding epitopes and different ligand‐binding inhibitory activity compared with cetuximab or panitumumab. GC1118 showed promising antitumor activity, especially in patients with colorecta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Oh, Do‐Youn, Lee, Keun‐Wook, Han, Sae‐Won, Kim, Jin Won, Shin, Jung‐Won, Jo, Seong‐Jin, Won, Jonghwa, Hahn, Seokyung, Lee, Howard, Kim, Woo Ho, Bang, Yung‐Jue
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Clinical Trial Results
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6693725/
https://ncbi.nlm.nih.gov/pubmed/31164456
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0294
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados